Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence

Abstract Background Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real‐world data of ALK TKIs remain a major concern. Methods Patients with ALK‐positive advanced NSCLC, who recei...

書目詳細資料
發表在:	Cancer Medicine
Main Authors:	Yurong Wang, Shujing Shen, Peizhu Hu, Di Geng, Ruipan Zheng, Xingya Li
格式:	Article
語言:	英语
出版:	Wiley 2022-12-01
主題:	alectinib ALK brigatinib ceritinib crizotinib PFS
在線閱讀:	https://doi.org/10.1002/cam4.4834

相似書籍

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
由: Chih-Hsi Scott Kuo, et al.
出版: (2021-03-01)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
由: Liu M, et al.
出版: (2019-10-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
由: Caicun Zhou, MD, PhD, et al.
出版: (2024-09-01)

Modern treatment of ALK-positive non-small cell lung cancer
由: D. A. Kharagezov, et al.
出版: (2022-06-01)

CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
由: N. V. Mitiushkina, et al.
出版: (2020-09-01)

Role and targeting of anaplastic lymphoma kinase in cancer
由: Carminia Maria Della Corte, et al.
出版: (2018-02-01)

Real‐World Outcomes of Brigatinib Compared to Alectinib as a Second‐Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non‐Small Cell Lung Cancer Patients
由: Min Jee Kim, et al.
出版: (2025-10-01)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
由: Gianluca Spitaleri, et al.
出版: (2023-05-01)

Current approaches to therapy of ALK-positive non-small cell lung cancer
由: К. К. Laktionov, et al.
出版: (2021-06-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
由: S. G. Bagrova, et al.
出版: (2019-12-01)

Drug interactions between ALK inhibitors and warfarin with concurrent use of bucolome: a case report
由: Takashi Kato, et al.
出版: (2023-05-01)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
由: Luca Mastrantoni, et al.
出版: (2024-01-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
由: Jing ZHAO, et al.
出版: (2015-10-01)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
由: Valerio Gristina, et al.
出版: (2020-12-01)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
由: Emilio Francesco Giunta, et al.
出版: (2022-06-01)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
由: Ibiayi Dagogo-Jack, MD, et al.
出版: (2023-08-01)

Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
由: Yuhang Zhou, et al.
出版: (2023-11-01)

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
由: Cesare Gridelli, et al.
出版: (2023-11-01)

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
由: Lee AT, et al.
出版: (2023-07-01)

Safety of brigatinib following alectinib-induced-pneumonitis: Case report
由: Blerina Resuli, et al.
出版: (2025-01-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
由: Chang Liu, et al.
出版: (2019-10-01)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
由: Naoko Imanishi, et al.
出版: (2018-03-01)

Inflammatory myofibroblastic tumors in children: clinical characteristics and treatment outcomes with a focus on targeted therapies
由: Ülkü Miray Yıldırım, et al.
出版: (2025-02-01)

Novel PLEC-EML4-ALK Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report
由: Alessandra Maleddu, MD, et al.
出版: (2025-05-01)

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
由: Justin M. Cheung, MD, et al.
出版: (2024-03-01)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
由: Peng Song, et al.
出版: (2019-04-01)

Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
由: Akhil Kapoor, et al.
出版: (2023-04-01)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001
由: Terry L. Ng, et al.
出版: (2022-12-01)

Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India
由: Ajaykumar Singh, et al.

Observation of Alectinib‐ and Crizotinib‐ included chemotherapy in children with ALK‐positive anaplastic large cell lymphoma: A single institutional experience
由: Yingyi He, et al.
出版: (2023-03-01)

Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report
由: Xinyi WANG, et al.
出版: (2024-12-01)

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
由: Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, et al.
出版: (2021-03-01)

Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib
由: Xiaoqian Zhai, et al.
出版: (2023-03-01)

Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib
由: Bole Li, et al.
出版: (2023-11-01)

A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
由: Zhongzhao Wang, et al.
出版: (2024-11-01)

Successful use of enteric alectinib in a critically ill patient with metastatic ALK-adenocarcinoma: A case report
由: Maria Braganca, et al.
出版: (2025-12-01)

The Dual Role of Autophagy in Crizotinib-Treated ALK<sup>+</sup> ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
由: Estelle Espinos, et al.
出版: (2021-09-01)

Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review
由: Pei Li, et al.
出版: (2024-02-01)

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib
由: Yuki Sato, et al.
出版: (2024-08-01)

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient
由: Kaili Huang, et al.
出版: (2025-04-01)